Price Action Alert: Could Uniqure NV See a Reversal After This Very Weak Session?

Price Action Alert: Could Uniqure NV See a Reversal After This Very Weak Session?

The stock of Uniqure NV (NASDAQ:QURE) is a huge mover today! About 253,814 shares traded hands or 10.03% up from the average. Uniqure NV (NASDAQ:QURE) has declined 35.11% since April 13, 2016 and is downtrending. It has underperformed by 39.03% the S&P500.
The move comes after 5 months negative chart setup for the $194.03M company. It was reported on Nov, 15 by Barchart.com. We have $6.90 PT which if reached, will make NASDAQ:QURE worth $21.34 million less.

Uniqure NV (NASDAQ:QURE) Ratings Coverage

Out of 9 analysts covering uniQure N.V. (NASDAQ:QURE), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. uniQure N.V. has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. WallachBeth Capital maintained the stock with “Buy” rating in Friday, August 28 report. The stock has “Outperform” rating given by Leerink Swann on Tuesday, September 22. As per Monday, September 21, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating given on Tuesday, December 1 by WallachBeth Capital. Oppenheimer maintained the shares of QURE in a report on Monday, September 21 with “Outperform” rating. Chardan Capital Markets maintained the shares of QURE in a report on Thursday, October 1 with “Buy” rating. The stock has “Buy” rating given by Roth Capital on Monday, September 21. The rating was maintained by Piper Jaffray on Friday, August 28 with “Overweight”. The rating was downgraded by Zacks on Tuesday, September 1 to “Buy”. The stock of Uniqure NV (NASDAQ:QURE) has “Buy” rating given on Thursday, August 27 by Chardan Capital Markets.

According to Zacks Investment Research, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.”

Another recent and important Uniqure NV (NASDAQ:QURE) news was published by Fool.com which published an article titled: “Why uniQure NV Stock Skyrocketed Today” on April 06, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment